An application of pharmacometrics to individualize dosing of pemetrexed.
For anticancer drugs with a narrow therapeutic window, there is a delicate balance between efficacy and toxicity, thus it is pivotal to administer the right dose from the first administration onwards. Exposure of pemetrexed, a cytotoxic drug used in lung cancer treatment, is dictated by kidney function. To facilitate optimized dosing of pemetrexed, accurate prediction of drug clearance is pivotal. In the journal of anticancer chemotherapy and pharmacology Nikki Bleijs - de Rouw published her findings on endogenous biomarkers to predict pemetrexed pharmacokinetics. Nikki Bleijs - de Rouw showed that the combined CKD-EPI equation using both cystatin C and serum creatinine performed best in terms predicting pharmacokinetics of pemetrexed. This may facilitate dose individualization of pemetrexed. Read all about it here: https://lnkd.in/ehD98MUp Radboud Applied Pharmacometrics Radboudumc Radboudumc wetenschap